AI-generated summary
The authors reviewed recent literature on melasma and photobiomodulation, identifying nine relevant studies of clinical, in vitro and animal work. They report that photobiomodulation was associated with reduced melanin content and hyperpigmentation, along with reduced erythema and neovascularization, but say robust, well-designed clinical trials are needed to determine optimal light parameters.
- Studies included
- 9
- Who or what was studied
- Patients with melasma, plus in vitro and animal models
- Wavelengths
- 630, 585, 590, 830, 850 nm
- Limits stated in the abstract
- The abstract states that robust, well-designed clinical trials are needed and that optimal light parameters remain undetermined.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm, 590 nm, 850 nm
- Energy density (fluence)
- 20 J/cm2
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.